作者
Roxana Mehran, Usman Baber, Samin K Sharma, David J Cohen, Dominick J Angiolillo, Carlo Briguori, Jin Y Cha, Timothy Collier, George Dangas, Dariusz Dudek, Vladimír Džavík, Javier Escaned, Robert Gil, Paul Gurbel, Christian W Hamm, Timothy Henry, Kurt Huber, Adnan Kastrati, Upendra Kaul, Ran Kornowski, Mitchell Krucoff, Vijay Kunadian, Steven O Marx, Shamir R Mehta, David Moliterno, E Magnus Ohman, Keith Oldroyd, Gennaro Sardella, Samantha Sartori, Richard Shlofmitz, P Gabriel Steg, Giora Weisz, Bernhard Witzenbichler, Ya-ling Han, Stuart Pocock, C Michael Gibson
发表日期
2019/11/21
期刊
New England Journal of Medicine
卷号
381
期号
21
页码范围
2032-2042
出版商
Massachusetts Medical Society
简介
Background
Monotherapy with a P2Y12 inhibitor after a minimum period of dual antiplatelet therapy is an emerging approach to reduce the risk of bleeding after percutaneous coronary intervention (PCI).
Methods
In a double-blind trial, we examined the effect of ticagrelor alone as compared with ticagrelor plus aspirin with regard to clinically relevant bleeding among patients who were at high risk for bleeding or an ischemic event and had undergone PCI. After 3 months of treatment with ticagrelor plus aspirin, patients who had not had a major bleeding event or ischemic event continued to take ticagrelor and were randomly assigned to receive aspirin or placebo for 1 year. The primary end point was Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding. We also evaluated the composite end point of death from any cause, nonfatal myocardial infarction, or nonfatal stroke, using a noninferiority …
学术搜索中的文章
R Mehran, U Baber, SK Sharma, DJ Cohen… - New England Journal of Medicine, 2019